Yeah. It was eating at me the details and knowing business as to why it tanked. Its been low over PH3 results that match competitors on MDS. That cancer hasn't had a new drug in 15 years...makes no sense. Market over reaction lmao.
3k% increase YOY for sales yet it was @$2.5 around this time last year.
Honestly I dont see it getting back to 2.5 without FDA approval that was submitted in July being approved. Another would be actual data for combination of Regosurtib and ON. drugs passing for breast or colon cancer.
Still it shouldn't be even this low. Being this close to approval with data backing results is profit city in a few months. Just my opinion.
News 
Market Data 
Discover 
